Broadcast Date: 
  • Time: 

Blocking the pathway that shields cancer cells from being targeted by the immune system is the foundation of immunotherapies that have been effective in treating aggressive cancers such as metastatic melanoma. PD-1–and MAPK–targeted therapies were first developed successfully in melanoma. Yet, resistance to these therapies can be innate or acquired, severely limiting ultimate survival benefits. Transcriptional analysis of tumor cell populations has uncovered important disease signatures and could provide the key to identifying the underlying mechanisms to improve therapeutic responses.

In this GEN webinar, our distinguished guest speaker Dr. Roger Lo will provide insights into his current research on MAP kinase targeted therapies and checkpoint inhibitors for melanoma. Moreover, we will learn how a mechanistic understanding for rationally deploying these treatments together and identifying additional novel targets will serve as a model to improve survival for patients with melanoma and other common cancers.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.

Roger Lo, MD, PhD
Roger Lo, MD, PhD
Prof. of Medicine, Dermatology, and Molecular & Medical Pharmacology
Assoc. Chief, Division of Dermatology
David Geffen School of Medicine at UCLA

Produced with support from:

10x Genomics logo